<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35901993</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-3296</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>American journal of infection control</Title><ISOAbbreviation>Am J Infect Control</ISOAbbreviation></Journal><ArticleTitle>Nosocomial COVID-19 at a comprehensive cancer center during the first year of the pandemic: Lessons learned.</ArticleTitle><Pagination><StartPage>506</StartPage><EndPage>513</EndPage><MedlinePgn>506-513</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajic.2022.07.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0196-6553(22)00575-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">The spread of coronavirus disease 2019 (COVID-19) in health care settings endangers patients with cancer. As knowledge of the transmission of COVID-19 emerged, strategies for preventing nosocomial COVID-19 were updated. We describe our early experience with nosocomial respiratory viral infections (RVIs) at a cancer center in the first year of the pandemic (March 2020-March 2021).</AbstractText><AbstractText Label="METHODS">Nosocomial RVIs were identified through our infection control prospective surveillance program, which conducted epidemiologic investigations of all microbiologically documented RVIs. Data was presented as frequencies and percentages or medians and ranges.</AbstractText><AbstractText Label="RESULTS">A total of 35 of 3944 (0.9%) documented RVIs were determined to have been nosocomial acquired. Majority of RVIs were due to SARS CoV-2 (13/35; 37%) or by rhinovirus/enterovirus (12/35; 34%). A cluster investigation of the first 3 patients with nosocomial COVID-19 determined that transmission most likely occurred from employees to patients. Five patients (38%) required mechanical ventilation and 4 (31%) died during the same hospital encounter.</AbstractText><AbstractText Label="CONCLUSIONS">Our investigation of the cluster led to enhancement of our infection control measures. The implications of COVID-19 vaccination on infection control policies is still unclear and further studies are needed to delineate its impact on the transmission of COVID-19 in a hospital setting.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khawaja</LastName><ForeName>Fareed</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srinivasan</LastName><ForeName>Krithika</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spallone</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Adina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantu</LastName><ForeName>Sherry</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ariza-Heredia</LastName><ForeName>Ella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dvordak</LastName><ForeName>Tanya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alousi</LastName><ForeName>Amin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Sairah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>George</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Office of Chief Operating Officer, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frenzel</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatti</LastName><ForeName>Micah</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chemaly</LastName><ForeName>Roy F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX; Office of Chief Operating Officer, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: rfchemaly@mdanderson.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AI055413</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Infect Control</MedlineTA><NlmUniqueID>8004854</NlmUniqueID><ISSNLinking>0196-6553</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003428" MajorTopicYN="Y">Cross Infection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hospital-associated transmission</Keyword><Keyword MajorTopicYN="N">Immunocompromised</Keyword><Keyword MajorTopicYN="N">Malignancy</Keyword><Keyword MajorTopicYN="N">Respiratory viruses</Keyword><Keyword MajorTopicYN="N">SARS CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>25</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>28</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35901993</ArticleId><ArticleId IdType="pmc">PMC9310434</ArticleId><ArticleId IdType="doi">10.1016/j.ajic.2022.07.019</ArticleId><ArticleId IdType="pii">S0196-6553(22)00575-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou Q, Gao Y, Wang X, et al. Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis. Ann Transl Med. 2020;8:629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7290630</ArticleId><ArticleId IdType="pubmed">32566566</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus&#x2013;Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter B, Collins JT, Barlow-Pay F, et al. Nosocomial COVID-19 infection: examining the risk of mortality. The COPE-Nosocomial Study (COVID in Older PEople) J Hosp Infect. 2020;106:376&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7372282</ArticleId><ArticleId IdType="pubmed">32702463</ArticleId></ArticleIdList></Reference><Reference><Citation>Wake RM, Morgan M, Choi J, Winn S. Reducing nosocomial transmission of COVID-19: implementation of a COVID-19 triage system. Clin Med (Lond) 2020;20:e141&#x2013;e145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7539706</ArticleId><ArticleId IdType="pubmed">32788160</ArticleId></ArticleIdList></Reference><Reference><Citation>Waghmare A, Abidi MZ, Boeckh M, et al. Guidelines for COVID-19 management in hematopoietic cell transplantation and cellular therapy recipients. Biol Blood Marrow Transpl. 2020;26:1983&#x2013;1994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7386267</ArticleId><ArticleId IdType="pubmed">32736007</ArticleId></ArticleIdList></Reference><Reference><Citation>Reidy-Lagunes D, Saltz L, Postow M, et al. Recommendations for testing and treating outpatient cancer patients in the Era of COVID-19. J Natl Cancer Inst. 2021;113:820&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454724</ArticleId><ArticleId IdType="pubmed">32797188</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofori-Asenso R, Ogundipe O, Agyeman AA, et al. Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis. Ecancermedicalscience. 2020;14:1047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289619</ArticleId><ArticleId IdType="pubmed">32565900</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyashita H, Mikami T, Chopra N, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol. 2020;31:1088&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172785</ArticleId><ArticleId IdType="pubmed">32330541</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkrief A, Desilets A, Papneja N, et al. High mortality among hospital-acquired COVID-19 infection in patients with cancer: a multicentre observational cohort study. Eur J Cancer. 2020;139:181&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7470707</ArticleId><ArticleId IdType="pubmed">33035991</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 2020;10:935&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334098</ArticleId><ArticleId IdType="pubmed">32357994</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: a critical review on the unresolved dichotomy. Environ Res. 2020;188</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7293495</ArticleId><ArticleId IdType="pubmed">32569870</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol. 2020;6:1108&#x2013;1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097836</ArticleId><ArticleId IdType="pubmed">32211820</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen PZ, Bobrovitz N, Premji Z, Koopmans M, Fisman DN, Gu FX. Heterogeneity in transmissibility and shedding SARS-CoV-2 via droplets and aerosols. Elife. 2021;10:e65774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139838</ArticleId><ArticleId IdType="pubmed">33861198</ArticleId></ArticleIdList></Reference><Reference><Citation>Triggle CR, Bansal D, Ding H, et al. A comprehensive review of viral characteristics, transmission, pathophysiology, immune response, and management of SARS-CoV-2 and COVID-19 as a basis for controlling the pandemic. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7952616</ArticleId><ArticleId IdType="pubmed">33717166</ArticleId></ArticleIdList></Reference><Reference><Citation>Goins WP, Talbot HK, Talbot TR. Health care-acquired viral respiratory diseases. Infect Dis Clin North Am. 2011;25:227&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4170875</ArticleId><ArticleId IdType="pubmed">21316002</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar-Compte D, Shah DP, Vanichanan J, et al. Influenza in patients with hematological malignancies: Experience at two comprehensive cancer centers. J Med Virol. 2018;90:50&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5761331</ArticleId><ArticleId IdType="pubmed">28851056</ArticleId></ArticleIdList></Reference><Reference><Citation>Khawaja F, Chemaly RF. Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies. Haematologica. 2019;104:1322&#x2013;1331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6601091</ArticleId><ArticleId IdType="pubmed">31221784</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah DP, Shah PK, Azzi JM, El Chaer F, Chemaly RF. Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: a systematic review. Cancer Lett. 2016;379:100&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4935561</ArticleId><ArticleId IdType="pubmed">27260872</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah DP, Shah PK, Azzi JM, Chemaly RF. Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: a systematic review. Cancer Lett. 2016;370:358&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4684719</ArticleId><ArticleId IdType="pubmed">26582658</ArticleId></ArticleIdList></Reference><Reference><Citation>Piralla A, Percivalle E, Di Cesare-Merlone A, Locatelli F, Gerna G. Multicluster nosocomial outbreak of parainfluenza virus type 3 infection in a pediatric oncohematology unit: a phylogenetic study. Haematologica. 2009;9:833&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688575</ArticleId><ArticleId IdType="pubmed">19377073</ArticleId></ArticleIdList></Reference><Reference><Citation>Greninger AL, Zerr DM, Qin X, et al. Rapid metagenomic next-generation sequencing during an investigation of hospital-acquired human parainfluenza virus 3 infections. J Clin Microbiol. 2017;55:177&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5228228</ArticleId><ArticleId IdType="pubmed">27795347</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen SJ, Winn AK, Budd AP, et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic - United States, 2020-2021. MMWR Morb Mortal Wkly Rep. 2021;70:1013&#x2013;1019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8297694</ArticleId><ArticleId IdType="pubmed">34292924</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong SC, Lam GK, AuYeung CH, et al. Absence of nosocomial influenza and respiratory syncytial virus infection in the coronavirus disease 2019 (COVID-19) era: Implication of universal masking in hospitals. Infect Control Hosp Epidemiol. 2021;42:218&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7468684</ArticleId><ArticleId IdType="pubmed">32799965</ArticleId></ArticleIdList></Reference><Reference><Citation>Long SW, Olsen RJ, Christensen PA, et al. Sequence analysis of 20,453 severe acute respiratory syndrome Coronavirus 2 genomes from the Houston Metropolitan Area identifies the emergence and widespread distribution of multiple isolates of all major variants of concern. Am J Pathol. 2021;191:983&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7962948</ArticleId><ArticleId IdType="pubmed">33741335</ArticleId></ArticleIdList></Reference><Reference><Citation>Responding to SARS-CoV-2 infections in acute care facilities. Accessed August 26, 2022. https://www.cdc.gov/coronavirus/2019-ncov/hcp/responding-acute-care-facilities.html</Citation></Reference><Reference><Citation>Rhee C, Baker M, Vaidya V, et al. Incidence of nosocomial COVID-19 in patients hospitalized at a large US Academic Medical Center. JAMA Network Open. 2020;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489854</ArticleId><ArticleId IdType="pubmed">32902653</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow K, Aslam A, McClure T, et al. Risk of healthcare-associated transmission of sever acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in hospitalized cancer patients. Clin Infect Dis. 2022;74:1579&#x2013;1585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8385815</ArticleId><ArticleId IdType="pubmed">34329418</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker MA, Rhee C, Tucker R, et al. Rapid control of hospital-based severe acute respiratory syndrome coronavirus 2 omicron clusters through daily testing and universal use of N95 respirators. Clin Infect Dis. 2022;75:e296&#x2013;e299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903387</ArticleId><ArticleId IdType="pubmed">35137035</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinadatha C, Jones LD, Choi H, et al. Transmission of SARS-CoV-2 in inpatient and outpatient settings in a veterans affairs health care system. Open Forum Infect Dis. 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8344547</ArticleId><ArticleId IdType="pubmed">34426792</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenisch JM, Schmid D, Kuo HW, et al. Hospital-acquired Clostridium difficile infection: determinants for severe disease. Eur J Clin Microbiol Infect Dis. 2012;31:1923&#x2013;1930.</Citation><ArticleIdList><ArticleId IdType="pubmed">22210266</ArticleId></ArticleIdList></Reference><Reference><Citation>Manchal N, Mohamed MRS, Ting M, et al. Hospital acquired viral respiratory tract infections: an underrecognized nosocomial infection. Infect Dis Health. 2020;25:175&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">32205064</ArticleId></ArticleIdList></Reference><Reference><Citation>Neubeiser A, Bonsignore M, Tafelski S, et al. Mortality attributable to hospital acquired infections with multidrug-resistant bacteria in a large group of German hospitals. J Infect Public Health. 2020;13:204&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">31420314</ArticleId></ArticleIdList></Reference><Reference><Citation>Matuschek C, Moll F, Fangerau H. Face masks: benefits and risks during the COVID-19 crisis. Eur J Med Res. 2020;25:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7422455</ArticleId><ArticleId IdType="pubmed">32787926</ArticleId></ArticleIdList></Reference><Reference><Citation>Karia R, Nagraj S. A review of viral shedding in resolved and convalescent COVID-19 patients. SN Compr Clin Med. 2020;2:2086&#x2013;2095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7471550</ArticleId><ArticleId IdType="pubmed">32901229</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, Bhatt NS, St Martin A. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8:e185&#x2013;ee93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816949</ArticleId><ArticleId IdType="pubmed">33482113</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalinsky K, Accordino MK, Hosi K, et al. Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City. Breast Cancer Res Treat. 2020;182:239&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7220807</ArticleId><ArticleId IdType="pubmed">32405915</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachem RY, Datoguia T, Siddiqui B, et al. 372. Comparing the outcome of COVID-19 in cancer and non-cancer patients: an International Multicenter Study. Open Forum Infectious Diseases. 2020;7(suppl 1) S256-S.</Citation></Reference><Reference><Citation>Tempia S, Walaza S, Bhiman JN, et al. Decline of influenza and respiratory syncytial virus detection in facility-based surveillance during the COVID-19 pandemic, South Africa, January to October 2020. Euro Surveill. 2021;26</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8299743</ArticleId><ArticleId IdType="pubmed">34296675</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley DA, Yeoh DK, Minney-Smith CA, et al. The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of Coronavirus disease 2019-related public health measures. Clin Infect Dis. 2021;73:e2829&#x2013;e2830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7929151</ArticleId><ArticleId IdType="pubmed">33594407</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>